BlackRock’s F-star Therapeutics, Inc. Common Stock FSTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q1
Sell
-297,433
Closed -$1.88M 5782
2022
Q4
$1.88M Sell
297,433
-370
-0.1% -$2.05K ﹤0.01% 4160
2022
Q3
$1.52M Buy
297,803
+950
+0.3% +$5.96K ﹤0.01% 4317
2022
Q2
$1.86M Buy
296,853
+906
+0.3% +$3.05K ﹤0.01% 4280
2022
Q1
$1.05M Buy
295,947
+4,776
+2% +$17.6K ﹤0.01% 4650
2021
Q4
$1.46M Buy
291,171
+1,783
+0.6% +$10.8K ﹤0.01% 4522
2021
Q3
$2.12M Buy
289,388
+638
+0.2% +$4.38K ﹤0.01% 4301
2021
Q2
$2.48M Buy
288,750
+244,227
+549% +$2.08M ﹤0.01% 4168
2021
Q1
$482K Sell
44,523
-297
-0.7% -$2.88K ﹤0.01% 4615
2020
Q4
$443K Sell
44,820
-1,057
-2% -$6.92K ﹤0.01% 4369
2020
Q3
$245K Buy
45,877
+4
+0% +$24 ﹤0.01% 4375
2020
Q2
$270K Sell
45,873
-8,371
-15% -$48.4K ﹤0.01% 4317
2020
Q1
$201K Buy
54,244
+465
+0.9% +$2.41K ﹤0.01% 4226
2019
Q4
$340K Buy
53,779
+1,573
+3% +$20K ﹤0.01% 4230
2019
Q3
$718K Buy
52,206
+1,313
+3% +$21.6K ﹤0.01% 4083
2019
Q2
$751K Sell
50,893
-120,339
-70% -$3.22M ﹤0.01% 4099
2019
Q1
$7.18M Buy
171,232
+2,399
+1% +$101K ﹤0.01% 3264
2018
Q4
$7.02M Buy
168,833
+17,816
+12% +$801K ﹤0.01% 3260
2018
Q3
$7.28M Buy
151,017
+30,202
+25% +$1.51M ﹤0.01% 3372
2018
Q2
$5.73M Buy
120,815
+113,258
+1,499% +$6.28M ﹤0.01% 3465
2018
Q1
$465K Sell
7,557
-683
-8% -$36K ﹤0.01% 4060
2017
Q4
$443K Buy
8,240
+1,064
+15% +$63.3K ﹤0.01% 4073
2017
Q3
$483K Buy
7,176
+1,847
+35% +$106K ﹤0.01% 4067
2017
Q2
$288K Buy
5,329
+5,288
+12,898% +$245K ﹤0.01% 4162
2017
Q1
$1K Buy
+41
New +$1.41K ﹤0.01% 4982

BlackRock's FSTX Position: Q1 2023 in Review

BlackRock sold out of F-star Therapeutics, Inc. Common Stock (FSTX) in Q1 2023, closing a stake of 297,433 shares — an estimated $1.88M sold.

BlackRock first reported a position in FSTX in Q1 2017 and held it in 24 quarters. The position peaked at $7.28M in Q3 2018. 0 funds tracked by Wall St. Rank hold FSTX as of Q1 2023.

  • BlackRock reported no remaining F-star Therapeutics, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
  • BlackRock sold 297,433 F-star Therapeutics, Inc. Common Stock shares in Q1 2023, an estimated $1.88M.
  • BlackRock first reported a position in F-star Therapeutics, Inc. Common Stock in Q1 2017 and held it in 24 quarters.
  • BlackRock's F-star Therapeutics, Inc. Common Stock position peaked at $7.28M in Q3 2018.
  • 0 funds tracked by Wall St. Rank held F-star Therapeutics, Inc. Common Stock as of Q1 2023.

Based on BlackRock's 13F filing for Q1 2023, filed 12 May 2023.